ABC-06 results: Second-line ASC mFOLFOX chemotherapy for biliary tract cancer

Managing metastatic breast cancer and beyond using PARP inhibitors

POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer

Highlights from ASCO 2019

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent

Epigenetic expression in T cell leukaemia

B-lymphoid transcriptional programme as a barrier against malignant transformation in acute lymphoblastic leukaemia

Emerging role of radioembolization for hepatocellular carcinoma

Surgical management of pancreatic cancer

Advanced HCC: New systemic treatment options